The ongoing phase III GLOBRYTE study will further define its role by comparing glofitamab with bendamustine–rituximab or lenalidomide–rituximab in patients with R/R MCL previously treated with BTK inhibitors [30]. Here, BTK is linked to mantle cell lymphoma.